Nanexa AB (publ) (STO:NANEXA)
6.33
+0.51 (8.76%)
Sep 4, 2026, 5:29 PM CET
Nanexa AB Revenue
Nanexa AB had revenue of 6.16M SEK in the quarter ending June 30, 2026, a decrease of -61.69%. This brings the company's revenue in the last twelve months to 51.90M, up 9.76% year-over-year. In the year 2025, Nanexa AB had annual revenue of 63.44M with 34.14% growth.
Revenue (ttm)
51.90M
Revenue Growth
+9.76%
P/S Ratio
35.72
Revenue / Employee
1.99M
Employees
17
Market Cap
1.21B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.44M | 16.15M | 34.14% |
| Dec 31, 2024 | 47.29M | -12.20M | -20.50% |
| Dec 31, 2023 | 59.49M | 31.31M | 111.13% |
| Dec 31, 2022 | 28.18M | 10.02M | 55.15% |
| Dec 31, 2021 | 18.16M | -2.82M | -13.43% |
| Dec 31, 2020 | 20.98M | 12.25M | 140.30% |
| Dec 31, 2019 | 8.73M | 4.58M | 110.36% |
| Dec 31, 2018 | 4.15M | 895.19K | 27.50% |
| Dec 31, 2017 | 3.25M | 1.23M | 60.82% |
| Dec 31, 2016 | 2.02M | -189.15K | -8.55% |
| Dec 31, 2015 | 2.21M | - | - |
| Dec 31, 2014 | 0 | - | - |
| Apr 30, 2014 | 186.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.58B |
| EQL Pharma AB | 432.35M |
| Enzymatica AB | 51.93M |
| Cinclus Pharma Holding AB | 35.18M |
| Newbury Pharmaceuticals AB | 35.02M |
| Moberg Pharma AB | 16.76M |
| Orexo AB | 16.60M |
| Dicot Pharma AB | 200.00K |
Nanexa AB News
- 8 days ago - Nanexa AB Quarterly report: Q2 2026 - Filings
- 4 months ago - Nanexa AB Quarterly report: Q1 2026 - Filings
- 6 months ago - Nanexa AB Annual report: Q4 2025 - Filings
- 6 months ago - Nanexa AB Quarterly report: Q4 2025 - Filings
- 10 months ago - Nanexa AB Quarterly report: Q3 2025 - Filings